Harvard Bioscience, Inc. (HBIO)

Over the past six months, HBIO's stock price has been impacted by several events. The stock rose in January 2026 after announcing a plan to reshape its production footprint. On March 13, 2026, the company enacted a 1-for-10 reverse stock split. Q4 2025 financial results were reported on March 12, 2026, with revenue of $23.7 million, a 3.2% year-over-year decline, but the gross margin reached a seven-quarter high. Full-year 2025 revenue was $86.6 million, down from $94.1 million in 2024, partly due to tariffs and delayed NIH funding. A $48.0 million goodwill impairment charge in Q1 2025 contributed to a net loss of $(56.7) million for the year. In November 2025, Q3 2025 financial results were announced, highlighting growth opportunities and efforts to strengthen its capital structure. In August 2025, analysts lowered their average price target for HBIO by 33% to $3.00. The stock has experienced a significant decline, losing over 69% in the past year as of January 30, 2026, and a 13.36% decline between March 25, 2025, and March 24, 2026.

Harvard Bioscience experiences demand seasonality for its products and services, with Q1 2025 revenues reflecting typical Q4 to Q1 seasonality. This seasonality is also influenced by factors such as uncertainty surrounding NIH funding and evolving tariff situations, particularly concerning sales to China. Government shutdowns can also affect the company's ability to achieve its goals within a quarter.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company operates in the analytical laboratory instrument manufacturing industry and the Healthcare sector. Its product portfolio supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing. Its customer base includes academic institutions, government laboratories, pharmaceutical companies, biotechnology firms, and contract research organizations.

Harvard Bioscience has a global presence with operations in the United States, Europe, and China, selling its products through direct sales and distribution partners. It has manufacturing facilities in multiple locations but is consolidating its production footprint, closing the Holliston, Massachusetts plant and shifting output to other sites. A significant portion of its revenue is generated from the United States.

In the past year, Harvard Bioscience has focused on a strategic transformation to become a leading enabler of translational science. This involves aligning with New Approach Methodologies and emphasizing products that facilitate more accurate, human-relevant data earlier in drug development. The company has also highlighted its acceleration of high-margin innovation and operational excellence, including manufacturing consolidation and cost reductions. The successful refinancing of its debt in December 2025 also contributes to a stronger financial reputation.

Harvard Bioscience's ownership structure includes institutional, retail, and individual investors. Institutional investors hold a substantial portion of the company's stock, with a majority of the outstanding shares. Major institutional owners include AMH Equity Ltd, Weber Capital Management Llc /adv, Vanguard Group Inc, Acadian Asset Management Llc, Meros Investment Management, LP, Corsair Capital Management, L.p., Renaissance Technologies Llc, Two Sigma Investments, Lp, Two Sigma Advisers, Lp, and BlackRock, Inc. Insiders own approximately 10.28% of the stock, and James W. Green owns the most individual shares.